These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 19438555)
21. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. Bandino JP; Perry DM; Clarke CE; Marchell RM; Elston DM J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e378-e380. PubMed ID: 28222231 [No Abstract] [Full Text] [Related]
22. A Case of Ixekizumab-induced Psoriasiform Eruption. Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870 [No Abstract] [Full Text] [Related]
25. [Eventration and methotrexate in psoriasis]. Schmutz JL; Barbaud A; Trechot P Ann Dermatol Venereol; 2010 Oct; 137(10):672. PubMed ID: 20932456 [No Abstract] [Full Text] [Related]
26. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis. Imafuku S; Ito K; Nakayama J Br J Dermatol; 2012 Mar; 166(3):675-8. PubMed ID: 21910704 [No Abstract] [Full Text] [Related]
27. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema. Kimura R; Sugita K; Yamamoto O Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034 [No Abstract] [Full Text] [Related]
28. Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate. Sako EY; Famenini S; Wu JJ J Am Acad Dermatol; 2013 Nov; 69(5):e264-e265. PubMed ID: 24124857 [No Abstract] [Full Text] [Related]
29. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system. Aggarwal P Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310 [No Abstract] [Full Text] [Related]
30. Nummular dermatitis on guselkumab for palmoplantar psoriasis. Truong A; Le S; Kiuru M; Maverakis E Dermatol Ther; 2019 Jul; 32(4):e12954. PubMed ID: 31070862 [TBL] [Abstract][Full Text] [Related]
31. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Yawalkar N; Hunger RE Dermatology; 2009; 218(1):79-83. PubMed ID: 18974629 [No Abstract] [Full Text] [Related]
32. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Parakh S; Nguyen R; Opie JM; Andrews MC Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423 [TBL] [Abstract][Full Text] [Related]
33. Enoxaparin sodium-induced bullous pemphigoid-like eruption: a report of 2 cases. Dyson SW; Lin C; Jaworsky C J Am Acad Dermatol; 2004 Jul; 51(1):141-2. PubMed ID: 15243541 [No Abstract] [Full Text] [Related]
34. Safety and tolerability of calcipotriol in psoriasis. Br J Clin Pract Suppl; 1996 Feb; 83():26-8. PubMed ID: 8871486 [No Abstract] [Full Text] [Related]
35. Development of primary varicella infection during infliximab treatment for psoriasis. Balato N; Gaudiello F; Balato A; Ayala F J Am Acad Dermatol; 2009 Apr; 60(4):709-10. PubMed ID: 19293027 [No Abstract] [Full Text] [Related]
36. [Patient education. Information letter on treatment of psoriasis with adalimumab (Humira)]. Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011 Ann Dermatol Venereol; 2011 Dec; 138(12):868-70. PubMed ID: 22137634 [No Abstract] [Full Text] [Related]